NR-55418来自SARS相关冠状病毒2的刺突糖蛋白S1结构域,带有C末端组氨酸标签的D614G变体,来自HEK293细胞的重组(蛋白质）
A recombinant form of the spike (S) glycoprotein S1 domain from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), D614G variant was produced by transient transfection in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55418 lacks the signal sequence, contains 670 residues of the SARS-CoV-2 S glycoprotein (amino acid residues V16 to R685) and features a C-terminal poly-histidine tag. NR-55418 is a variant of SARS-CoV-2 which contains the D614G mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55418 has a theoretical molecular weight of 76,800 daltons. The crystal structure for the wild-type S glycoprotein from SARS-CoV-2 has been solved at 2.8 ? resolution (PDB: 6VXX).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The D614G mutation is common to the current variants of interest and concern identified by the Centers for Disease Control and Prevention (CDC). This mutation was one of the first documented in the USA in the initial stages of the pandemic after having initially circulated in Europe. Some evidence suggests that variants with the D614G mutation are more infectious than wild-type.
The biological activity of NR-55418 was measured by its binding ability in a functional ELISA, in which immobilized NR-55418 at 2 ?g per mL (100 ?L per well) can bind human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257); the linear range is 0.2 to 3 ng per mL. Immobilized NR-55418 at 2 ?g
per mL (100 ?L per well) can also bind Anti-SARS-CoV-2 neutralizing antibody (ACROBiosystems SAD-S35); the linear range is 0.2 to 3 ng per mL. The biological activity of NR-55418 was also
measured by its binding ability using biosensor analysis, in which loaded ACROBiosystems AC2-H5257 can bind NR-55418; the affinity constant is 76.4 nM by ForteBio Octet Red96e.
Each vial contains approximately 100 ?g of purified recombinant protein lyophilized in phosphate-buffered saline, pH 7.4 and 10% trehalose.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
